IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11273217 B1

PDFFull Text
Date of Patent:
Mar. 15, 2022

Filed:

Sep. 09, 2016

Cancer treatment composition combining anti-cd26 antibody and other anticancer agent

Applicant:

Y's Ac Co., Ltd., Tokyo, JP;

Inventors:

Taketo Yamada, Tokyo, JP;

Mutsumi Hayashi, Tokyo, JP;

Kohji Yamada, Tokyo, JP;

Chikao Morimoto, Tokyo, JP;

Toshihiro Okamoto, Koshigaya, JP;

Yutaro Kaneko, Tokyo, JP;

Assignee:

Y's AC Co., Ltd., Tokyo, JP;

Attorney:

Knobbe Martens Olson & Bear, LLP

Primary Examiner:

Nelson B Moseley, II

Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 31/343 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/7068 (2006.01); A61K 47/68 (2017.01); G01N 33/574 (2006.01); G01N 33/50 (2006.01); C07K 16/40 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/395 (2013.01); A61K 31/343 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6857 (2017.08); A61K 47/6871 (2017.08); A61P 35/00 (2018.01); C07K 16/2896 (2013.01); C07K 16/40 (2013.01); G01N 33/5011 (2013.01); G01N 33/57423 (2013.01); A61K 2039/505 (2013.01); A61K 2300/00 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/52 (2013.01);
Abstract

Mesothelioma growth inhibitory effect of standard cisplatin-pemetrexed concomitant therapy is potentiated by combination with an anti-CD26 antibody. A high therapeutic effect and excellent safety is obtained by the concomitant use of an anti-CD26 antibody and gemcitabine. By conjugating an anti-CD26 antibody (YS110) with triptolide via a divalent cross-linking agent for concomitant therapy using the anti-CD26 antibody, a novel antibody-drug conjugate (Y-TR1) very highly effective for CD26-positive malignant mesothelioma cells has been successfully obtained.

Find Patent Forward Citations

Loading…